Stock Evaluator: Altimmune, Inc. (ALT)

Altimmune, Inc. ALT

$1.33 -0.08 -5.67%
November 20, 2026 4:00:01 PM EST November 10, 2021 Volume: 4,019,048
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Commentary & Analysis


Financial Summary

Share Statistics ALT Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $258.8 $203.5 32%
Shares Out (Mil) 205.3 55.2 76%
Institutional Ownership 99.2% 93.3% 85%
Float (Mil) 174.3 40.4 71%
Beta 0.15 1.05 10%
Avg Daily Volume (000s) 5,068 569 92%
Price Change
(52-week)
(71.0%) 38.8% 13%
Growth ALT Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) (12.4%) (10.7%) 27%
EPS (5yr) 12.2% 15.4% 51
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (54.6%) (15.7%) 6%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 6 6 6
Current EPS ($0.177) ($0.627) ($0.712)
Month Ago EPS ($0.160) ($0.588) ($0.668)
# Rev Up 1 0 0
# Rev Down 1 1 1
Three Months Ago EPS ($0.160) ($0.588) ($0.668)
Year/Year Chg 14.9% (37.3%) (23.8%)
Financials ALT Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $40 na
Net Income (TTM) (Mil) ($104) ($44) 11%
EPS (TTM) ($0.671) ($1.400) 24%
Operating Cash Flow (TTM) (Mil) ($102) ($35) 6%
Net Cash Flow (TTM) (Mil) ($32) $-0 24%
Long-Term Debt (Q1) (Mil) $36 $4 36%
Enterprise Value (Q1) (Mil) $91 $142 21%
Valuation ALT Industry
Median
Percentile
(All Stocks)
P/B 0.58 1.96 15%
P/E na 16.9 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.9 na
Ratios ALT Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.6% na
Net Margin na (50.8%) na
ROA (29.2%) (47.0%) 16%
ROE (33.2%) (51.8%) 19%
Liabilities to Assets 10.5% 29.6% 6%
F-Score 3 3 18%

Passing Stock Screens

As of 11/20/2026, from a list of 60 stock screening strategies, ALT meetings the criteria of 1 screen:

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors